89 results
6-K
EX-99.2
d3u77xaz lpv2foob
5 Dec 23
Current report (foreign)
8:50am
6-K
EX-99.2
9tfn3ye50pzlpnejg8ih
13 Nov 23
Current report (foreign)
6:10am
6-K
EX-99.2
9fxriqrl1t rah
21 Sep 23
Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
10:52am
6-K
EX-99.1
rwt9cu
7 Sep 23
Valneva and Pfizer Report Positive Pediatric and Adolescent Phase 2 Booster Results for Lyme Disease Vaccine Candidate
5:00pm
6-K
EX-99.1
9yn2xc1 5q
29 Aug 23
Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate
8:00am
6-K
EX-1.1
lhivfotqvj4z7n
30 Sep 22
Valneva Announces the Pricing of €102.9 Million Global Offering of American Depositary Shares and Ordinary Shares
4:22pm
424B5
ecoizq
30 Sep 22
Prospectus supplement for primary offering
4:09pm
424B5
z7kff
28 Sep 22
Prospectus supplement for primary offering
8:24pm